Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 9/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10692079 | 0.85 | ALPL (0.49) | ALPLCNR2EPAS1ACLYSLC22A12 | |
| SCHEMBL6260261 | 0.83 | ALPL (0.56) | ALPLCNR2ACLYSLC22A12 | |
| Hydrochloric Acid SCHEMBL28145247 | 0.82 | ALPL (0.50) | ALPLCNR2ACLY | |
| SCHEMBL8074968 | 0.80 | ALPL (0.48) | ALPLCA1CA2CA12CA9 | |
| SCHEMBL10498373 | 0.80 | ADRA1D (0.43) | PTGES2 | |
| SCHEMBL5594990 | 0.79 | CA1 (0.41) | CNR2CA1CA2CA12CA9 | |
| SCHEMBL21056199 | 0.78 | ALPL (0.45) | ALPLCNR2EPAS1ACLYSLC22A12 | |
| SCHEMBL27452475 | 0.77 | CA1 (0.46) | CA1CA2CA12CA9PTGES2 | |
| SCHEMBL5749988 | 0.77 | PKM (0.58) | ALPLCA1CA2CA12CA9 | |
| SCHEMBL10962606 | 0.77 | ALPL (0.44) | ALPLCNR2EPAS1ACLYSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0064322-B1 | BENZENESULFONYL ISOCYANATES, ISOTHIOCYANATES, CHLORIDES, AND SULFONAMIDES HAVING A FLUORINATED SUBSTITUENT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-05-22 | — | — | EP | claimed |
| EP-0064322-A2 | Benzenesulfonyl isocyanates, isothiocyanates, chlorides, and sulfonamides having a fluorinated substituent | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-11-10 | — | — | EP | claimed |
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3559007-A1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-10-30 | — | — | EP | disclosed |
| CN-110167946-A | Sulfonamide compounds with TNAP inhibitory activity | 第一三共株式会社 | 2019-08-23 | — | — | CN | disclosed |
| WO-2018119444-A1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-06-28 | — | — | WO | disclosed |
| CN-1142906-C | Intermediate for producing 2-trifluoromethoxy benzene sulfonamide | — | 2004-03-24 | — | — | CN | disclosed |
| CN-1308057-A | INtermediate for producing 2-trifluoromethoxy benzene sulfonamide | BAYER AG (DE) | 2001-08-15 | — | — | CN | disclosed |
| CN-1068872-C | Production method of 2-trifluoromethoxybenzenesulfonamide | BAYER AG (DE) | 2001-07-25 | — | — | CN | disclosed |
| EP-0863869-B1 | METHOD OF PREPARING 2-TRIFLUOROMETHOXYBENZENE SULPHONAMIDE | BAYER AG (DE) | 2000-08-16 | — | — | EP | disclosed |
| US-5925788-A | Method of preparing 2-trifluoromethoxy-benzenesulphonamide | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-20 | — | — | US | disclosed |
| CN-1202883-A | Production method of 2-trifluoromethoxybenzenesulfonamide | BAYER AG (DE) | 1998-12-23 | — | — | CN | disclosed |
| EP-0863869-A1 | METHOD OF PREPARING 2-TRIFLUOROMETHOXYBENZENE SULPHONAMIDE | BAYER AG (DE) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997019056-A1 | METHOD OF PREPARING 2-TRIFLUOROMETHOXYBENZENE SULPHONAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | ALPL 7/4885CNR2 1369/4885EPAS1 2727/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | ALPL 5/4885CNR2 1604/4885EPAS1 3341/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | ALPL 7/4885CNR2 1369/4885EPAS1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.